A new PET/CT test to find insulinoma using a GLP-1R tracer compared to an earlier tracer
Official title: [68Ga]Ga-HBED-CC-PEG6-Exendin-4 PET/CT Imaging in the Diagnosis of Insulinoma
Run by Peking Union Medical College Hospital · NCT07808879 · Data updated 2026-11-12
A GLP-1 receptor–targeted PET/CT imaging agent is being tested in adults with suspected or confirmed insulinoma to see if the PEG6-modified tracer locates tumors better than the original tracer.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 70 Years |
| Sex | All |
| Enrollment | 20 (estimated) |
| Sponsor | Peking Union Medical College Hospital Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Status | Recruiting |
| Started | October 1, 2026 |
| Main results expected | August 31, 2027 |
| Study ends | September 30, 2027 |
| Registry record updated | September 9, 2026 |
| Trial ID | NCT07808879 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults 18–70 with suspected or biochemically confirmed insulinoma who are scheduled for pancreatic surgery or biopsy within 30 days and can complete two GLP-1R–targeted PET/CT scans within a week.
✕Probably not a fit
Patients whose tumors do not show GLP-1R expression or who have contraindications to PET/CT imaging may not benefit from the tracers.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional study compares two PET/CT tracers that target GLP-1 receptors on insulinoma cells. Twenty adults will undergo two PET/CT scans within a week, one with the PEG6-modified tracer and one with the original tracer, to localize insulinomas before surgical confirmation. A subset of the first participants will have dynamic imaging to study tracer distribution and radiation dose. Surgical biopsy or resection within one month provides pathological confirmation to correlate with imaging results. The goal is to improve noninvasive localization of small insulinomas that are hard to detect with standard imaging.
Why it matters
Potential benefit: If successful, the PEG6 tracer could improve tumor localization, potentially guiding more accurate surgery and better symptom relief.
How similar studies have gone: GLP-1R–targeted tracers have shown promise in preclinical and early clinical work, suggesting potential benefit but requiring confirmation in this comparative study.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age between 18 and 70 years, male or female. 2. Clinically suspected insulinoma with biochemically proven endogenous hyperinsulinism. 3. Complete clinical information and conventional abdominal imaging data available. 4. Scheduled for pancreatic surgery or biopsy within 30 days after PET/CT examination for pathological confirmation. 5. Capable of completing two GLP-1R-targeted PET/CT scans within a 7-day interval. 6. Voluntarily provides written informed consent and cooperates with study procedures. Exclusion Criteria: 1. Pregnancy, suspected pregnancy, or lactating status. 2. Severe hepatic or renal dysfunction prohibiting radiotracer injection. 3. Known allergy or hypersensitivity to exendin-4, gallium-based tracers, or injection excipients. 4. Uncontrolled severe systemic diseases that preclude PET/CT acquisition.
Where it's running
-
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China Recruiting
Study contacts
- Study coordinator: Yaping Luo, MD
- Email: luoyaping@live.com
- Phone: 86-10-69154717
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
EUS-guided radiofrequency ablation for pancreatic insulinoma safety and effectiveness
This project will try EUS-guided radiofrequency ablation (EUS-RFA) to treat people with pathology-confirmed pancreatic insulinoma and compare safety and outcomes to historic surgical patients.
-
Endoscopic ultrasound-guided radiofrequency ablation for pancreatic and left adrenal lesions
This will try EUS-guided radiofrequency ablation to control symptoms and hormone-related problems in adults with small pancreatic neuroendocrine tumors (including insulinomas) or certain left adrenal adenomas.
-
Using PET/CT imaging to diagnose GLP-1 receptor related diseases
This study is testing a special imaging scan to see if it can help doctors better diagnose cancer in adults who may have diseases related to GLP-1 receptors.
-
Using Fluorodopa F 18 to locate insulin-producing tumors in patients with congenital hyperinsulinism
This study tests whether a special imaging technique using Fluorodopa F 18 can help find insulin-producing tumors in patients with congenital hyperinsulinism to improve their treatment.
-
Research on diagnosing and treating low blood sugar levels
This study is testing how to better diagnose and treat low blood sugar in people with insulinomas while they receive care at a special clinic.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.